A Phase I Study of BRCX014 to Investigate Dose-Ranging Safety and Pharmacokinetics in Adults With Glioblastoma (GBM) and Non-Methylated MGMT Gene Status
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Leaf Vertical
- 25 Feb 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
- 25 Feb 2019 Planned initiation date changed from 1 Oct 2018 to 1 Jun 2019.
- 03 Oct 2018 New trial record